TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05030753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSIPsmarter
Description: iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education (PE)
Description: he PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
Study: NCT06277882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAVRIX
Description: intramuscular injections
Study: NCT06010901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection
Description: TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab injection
Description: Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab injection
Description: Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsules
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study: NCT06277882

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAVRIX
Description: intramuscular injections
Study: NCT06269380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: During the procedure, endoscopic examination of the upper gastrointestinal tract was made. Biopsy sampling can be made during procedure if endoscopist deemed necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsy sampling
Description: The obtaining of biopsy samples for control purposes despite the absence of endoscopic pathology during esophagogastroduodenoscopy.
Study: NCT04982354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.
Study: NCT06181032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab: 1200mg or 20mg/kg, iv, D1, Q3W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 250 mg, po, QD, Q3W;
Study: NCT04982354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.
Study: NCT06181032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000 mg/m2, iv, 30min, D1, D8, Q3W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 25 mg/m2, iv, 30min, D1, D8, Q3W; Injection sequence: adebelizumab → gemcitabine → cisplatin (sequential interval of at least 30 min), 3 cycles of neoadjuvant therapy.
Study: NCT04798339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab Injection
Description: Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab Injection
Description: Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab Injection
Description: Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle
Study: NCT01273428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP011-101

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HP-828-101

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Study: NCT06419244

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Myosteatosis
Description: Determination of myosteatosis by imaging

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Myosteatosis
Description: Determination of myosteatosis by imaging
Study: NCT04930744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid, dose prescribed by participant's physician, will be taken by mouth daily. Isoniazid, is in a combination pill pack with the other standard ATT medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid, dose prescribed by participant's physician, will be taken by mouth daily. Isoniazid, is in a combination pill pack with the other standard ATT medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin, dose prescribed by participant's physician, will be taken by mouth daily. Rifampicin is in a combination pill pack with the other standard ATT medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin, dose prescribed by participant's physician, will be taken by mouth daily. Rifampicin is in a combination pill pack with the other standard ATT medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol, dose prescribed by participant's physician, will be taken by mouth daily. Ethambutol is in a combination pill pack with the other standard ATT medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol, dose prescribed by participant's physician, will be taken by mouth daily. Ethambutol is in a combination pill pack with the other standard ATT medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide, dose prescribed by participant's physician, will be taken by mouth daily. Pyrazinamide is in a combination pill pack with the other standard ATT medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide, dose prescribed by participant's physician, will be taken by mouth daily. Pyrazinamide is in a combination pill pack with the other standard ATT medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochoride
Description: Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to study twice daily through study week-12 (11 weeks total metformin treatment).
Study: NCT04919512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.
Study: NCT05687721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: copanlisib
Description: intravenous infusion (IV) at 60 mg on Day 1, 8 and 15 of each 4-week treatment cycle for up to 26 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 800 mg intravenous infusion on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
Study: NCT05063461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetanic stimulation
Description: For each participant, record the first concentration that ANI≥50 after the tetanic stimuli, as the sufficient concentration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin incision
Description: Infuse the sufficient concentration for at least 5min of the steady-state period, then surgical stimulus is applied. The surgical stimulus is defined as the first skin incision to establish pneumoperitoneum.
Study: NCT05866146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interprofessional rehabilitation program
Description: The interprofessional rehabilitation program includes a comprehensive assessment, intensified physical activities and exercises, pain education, psychotherapy, occupational therapy, ergonomic interventions, and psychosocial counselling in addition to the current treatment standards. The interprofessional rehabilitation program will be delivered in a combination of individual (one-to-one) and group sessions (in groups of 6 - 10 patients). Care providers will apply a combination of lectures and discussions, individual exercises, and group-based exercises and education. All sessions will be delivered face-to-face (in person). The intervention will be provided by a team of healthcare providers with different professional backgrounds and training. The interprofessional team may include experienced physicians (GPs), neurosurgeons, physiotherapists, nurses, occupational therapists, and clinical psychologists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual standard care
Description: Participants in this group will receive the usual care currently implemented mainly pharmacological treatment (pain medication), and back pain advice. The usual care in rare occasions may also include physical therapy such as exercise and massage.
Study: NCT06272409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEP114
Description: DEP114 oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine 0.5 MG/ML
Description: Desloratadine oral solution
Study: NCT06124430

Intervention type: OTHER
Intervention: ECOX box
Description: For the ECOX approach, they will have the various ECOX grids and a stopwatch at their disposal in the 2 units of the emergency department. There will be around thirty evaluation grids at their disposal. Students will choose the ECOX grid corresponding to a starting situation. Once the time limit has elapsed, they must compare their answers with the grid's expectations. Each completed grid will be returned to a drawer in the box, to assess adherence to the tool and suggestions for grid modifications, as well as any comments. Students will be able to use them as many times as they wish during the course and before the service ECOS.
Study: NCT05442424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Produce Voucher
Description: see arm/group description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-List Control
Description: see arm/group description
Study: NCT05102760

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block using FIC Proceedure
Description: Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
Study: NCT05092347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5459
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5458
Description: Administered by intravenous (IV) infusion
Study: NCT05158777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.
Description: live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection
Study: NCT05102760

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block using PENG Proceedure
Description: Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
Study: NCT05313529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study
Study: NCT05158777

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
Description: live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection
Study: NCT04845074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSA-group
Description: Anatomical total shoulder arthroplasty followed by standard rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-group
Description: The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
Study: NCT04982354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg/dose every six hours x 12 doses administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m2/day x 2 doses administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2/day x 5 doses administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor
Description: Allogeneic stem cell transplant infused intravenously
Study: NCT05204173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab, paclitaxel and S-1
Description: Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days with one week rest.
Study: NCT06068218

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy for the patient group
Description: The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet. For vitiligo patients, the biopsies will be taken on a non-depigmented skin.

Intervention type: OTHER
Group type: OTHER
Intervention: biopsy for the volunteer group
Description: A publicity in the hospital will announce the study, and will be use to recruit the healthy volunteers. The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet.
Study: NCT06228768

Intervention type: OTHER
Group type: OTHER
Intervention: Acupressure
Description: 9 acupoints will be stimulated for 3 minutes per point
Study: NCT06112639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DANCEREX-DTx
Description: DANCEREX treatment integrates the dance activities with an innovative motivational system into applied game~The patients will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair). In addition, the DANCEREX app involves a game dynamic in which the execution of the rehabilitation sessions feeds a digital book that allows the rehabilitation experience to be placed in a narrative context.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multidimensional dance-based program
Description: Multidimensional dance-based program provided via a digital medicine telerehabilitation platform. The patient will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Educational Program
Description: Subjects will view educational/informative videos on Tablet. The treatment will be provided via a digital medicine platform.
Study: NCT04722172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib for a minimum of 13 cycles and maximum 26 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered during Cycles 2-7.
Study: NCT05272150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as subcutaneous injection.
Study: NCT06097364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Administered by IV infusion, or subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered by IV infusion
Study: NCT06228768

Intervention type: OTHER
Group type: OTHER
Intervention: Acupressure
Description: 9 areas will be stimulated for 3 minutes per point
Study: NCT04891770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Administered as film-coated oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Administered as film-coated oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Administered as film-coated oral tablets
Study: NCT06097364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prenisolone
Description: Administered orally (PO)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/Prenisolone
Description: Administered orally (PO)
Study: NCT05904886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.